These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2127937)

  • 21. The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate.
    Bachus KE; Hughes CL; Haney AF; Dodson WC
    Fertil Steril; 1990 Jul; 54(1):27-31. PubMed ID: 2113488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro fertilization and embryo transfer in patients with endometriosis: impact of a gonadotrophin releasing hormone agonist.
    Oehninger S; Brzyski RG; Muasher SJ; Acosta AA; Jones GS
    Hum Reprod; 1989 Jul; 4(5):541-4. PubMed ID: 2507576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.
    Dada T; Salha O; Baillie HS; Sharma V
    Hum Reprod; 1999 Feb; 14(2):288-93. PubMed ID: 10099965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
    Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
    Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mid-luteal phase injection of subcutaneous leuprolide acetate improves live delivered pregnancy and implantation rates in younger women undergoing in vitro fertilization-embryo transfer (IVF-ET).
    Check JH; Wilson C; Cohen R; Choe JK; Corley D
    Clin Exp Obstet Gynecol; 2015; 42(4):427-8. PubMed ID: 26411204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.
    Gonen Y; Balakier H; Powell W; Casper RF
    J Clin Endocrinol Metab; 1990 Oct; 71(4):918-22. PubMed ID: 2119392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progesterone change in the late follicular phase affects pregnancy rates both agonist and antagonist protocols in normoresponders: a case-controlled study in ICSI cycles.
    Demir B; Kahyaoglu I; Guvenir A; Yerebasmaz N; Altinbas S; Dilbaz B; Dilbaz S; Mollamahmutoglu L
    Gynecol Endocrinol; 2016; 32(5):361-5. PubMed ID: 26654315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is measurement of progesterone level prior to FSH stimulation useful in GnRH-antagonist cycles?
    Listijono D; Kilani S; Tilia L; Garrett D; Chapman M
    Hum Fertil (Camb); 2015; 18(4):234-7. PubMed ID: 25997693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfer of frozen-thawed embryos in artificially prepared cycles with and without prior gonadotrophin-releasing hormone agonist suppression: a prospective randomized study.
    Simon A; Hurwitz A; Zentner BS; Bdolah Y; Laufer N
    Hum Reprod; 1998 Oct; 13(1O):2712-7. PubMed ID: 9804219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles.
    Kiliçdag EB; Haydardedeoglu B; Cok T; Hacivelioglu SO; Bagis T
    Arch Gynecol Obstet; 2010 Apr; 281(4):747-52. PubMed ID: 19862542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.
    Aboulghar MA; Marie H; Amin YM; Aboulghar MM; Nasr A; Serour GI; Mansour RT
    Reprod Biomed Online; 2015 Jan; 30(1):52-6. PubMed ID: 25456166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteal support after luteinizing hormone-releasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone.
    Buvat J; Marcolin G; Guittard C; Herbaut JC; Louvet AL; Dehaene JL
    Fertil Steril; 1990 Mar; 53(3):490-4. PubMed ID: 2407565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins].
    Ellenbogen A; David H; Libal Y; Ballas S
    Harefuah; 1995 Dec; 129(11):455-6, 536. PubMed ID: 8846950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relation between the outcome of IVF-ET and subtle rise in serum progesterone during the follicular phase stimulated with a combination of gonadotropin-releasing hormone analog and gonadotropin].
    Sekijima A
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):249-55. PubMed ID: 8492012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human chorionic gonadotropin, estradiol, and progesterone profiles in conception and nonconception cycles in an in vitro fertilization program.
    Hutchinson-Williams KA; Lunenfeld B; Diamond MP; Lavy G; Boyers SP; DeCherney AH
    Fertil Steril; 1989 Sep; 52(3):441-5. PubMed ID: 2776898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study.
    Lin H; Li Y; Li L; Wang W; Zhang Q; Chen X; Yang D
    Eur J Obstet Gynecol Reprod Biol; 2013 Apr; 167(2):171-5. PubMed ID: 23287635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luteal phase oestradiol and progesterone levels are stronger predictors than follicular phase follicle stimulating hormone for the outcome of in-vitro fertilization treatment in women with tubal infertility.
    Csemiczky G; Wramsby H; Landgren BM
    Hum Reprod; 1996 Nov; 11(11):2396-9. PubMed ID: 8981118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of long- and short-acting forms of gonadotrophin-releasing hormone analogues in women undergoing oocyte donation.
    Neuspiller F; Levy M; Remohí J; Ruiz A; Simón C; Pellicer A
    Hum Reprod; 1998 May; 13(5):1148-51. PubMed ID: 9647536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH).
    Chen QJ; Sun XX; Li L; Gao XH; Wu Y; Gemzell-Danielsson K; Cheng LN
    Acta Obstet Gynecol Scand; 2007; 86(7):849-54. PubMed ID: 17611831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.